All publications

2023

Saarikettu, J, Lehmusvaara, S, Pesu, M, Junttila, I, Partanen, J, Sipilä, P et al.. The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. FASEB Bioadv. 2023;5 (5):183-198. doi: 10.1096/fba.2022-00115. PubMed PMID:37151849 PubMed Central PMC10158624.
Pölläniemi, A, Virtanen, A, Silvennoinen, O, Haikarainen, T. Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening. SLAS Discov. 2023;28 (4):180-187. doi: 10.1016/j.slasd.2023.05.001. PubMed PMID:37149038 .
Virtanen, A, Palmroth, M, Liukkonen, S, Kurttila, A, Haikarainen, T, Isomäki, P et al.. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling. Arthritis Rheumatol. 2023;75 (11):2054-2061. doi: 10.1002/art.42547. PubMed PMID:37134144 .
Virtanen, AT, Haikarainen, T, Sampathkumar, P, Palmroth, M, Liukkonen, S, Liu, J et al.. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel). 2023;16 (1):. doi: 10.3390/ph16010075. PubMed PMID:36678572 PubMed Central PMC9865020.

Silvennoinen, O, Haikarainen, T, Virtanen, A. Aiming for the pocket. Nat Chem Biol. 2022;18 (12):1296-1297. doi: 10.1038/s41589-022-01120-5. PubMed PMID:36097296 .
Lehmusvaara, S, Haikarainen, T, Saarikettu, J, Martinez Nieto, G, Silvennoinen, O. Inhibition of RNA Binding in SND1 Increases the Levels of miR-1-3p and Sensitizes Cancer Cells to Navitoclax. Cancers (Basel). 2022;14 (13):. doi: 10.3390/cancers14133100. PubMed PMID:35804872 PubMed Central PMC9265050.

Raivola, J, Haikarainen, T, Abraham, BG, Silvennoinen, O. Janus Kinases in Leukemia. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040800. PubMed PMID:33672930 PubMed Central PMC7918039.